- Conditions
- Menopause
- Interventions
- Estradiol withdrawal, Fragmented sleep
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Menorrhagia
- Interventions
- Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills, Naproxen sodium pills, NovaSure® Radiofrequency Endometrial Ablation
- Drug · Device
- Lead sponsor
- Abimbola Famuyide
- Other
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Major Depressive Disorder
- Interventions
- Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Adenocarcinoma of the Prostate, Prostate Cancer
- Interventions
- Docetaxel, Estramustine, Casodex, Zoladex
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 1 more
- Conditions
- Perimenopausal Depression, Post Menopausal, Healthy, Depression
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neoplasms, Breast Neoplasms
- Interventions
- Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 6
- States / cities
- Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Metformin, Oral combined hormonal contraceptives
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years to 49 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Other Disorders of Bone Development and Growth
- Interventions
- Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR)
- Drug
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2028
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
- Interventions
- Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fertility, Contraception
- Interventions
- Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, GDC-0810
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 4 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ribociclib, Letrozole, Anastrozole, Goserelin, Tamoxifen, Fulvestrant
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 16
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 13 more
- Conditions
- Contraception, Ovulation Inhibition, Contraceptives, Oral
- Interventions
- EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,887 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
- Conditions
- Suicidal Ideation
- Interventions
- Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Adenocarcinoma of Endometrium
- Interventions
- Fulvestrant, Abemaciclib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Pelvic Pain, Endometriosis
- Interventions
- Psychophysical assessment, Psychophysical assessments of experimental pain, Blood, urine and saliva samples, Biopsy and surgery-related data.
- Other · Behavioral · Diagnostic Test + 1 more
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Neoplasms
- Interventions
- Fulvestrant, Sapanisertib
- Drug
- Lead sponsor
- Calithera Biosciences, Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- Alpelisib, Tucatinib, Fulvestrant
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
- Conditions
- Perimenopause-Related Depression
- Interventions
- Estradiol, ER Beta Agonist, Placebo, Provera
- Drug · Other
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breakthrough Bleeding
- Interventions
- DR-1031, Seasonale®, Portia®
- Drug
- Lead sponsor
- Duramed Research
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 567 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 50
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
- Conditions
- Postpartum Depression
- Interventions
- Estradiol, Placebo, Progesterone, leuprolide acetate
- Drug · Other
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Contraception
- Interventions
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
- Conditions
- Uterine Leiomyoma, Uterine Fibroids
- Interventions
- Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
- Interventions
- Palbociclib, Olaparib, Fulvestrant
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania